Administration of Ctla-4 blocking antibody reversed changes in immune infiltrate as well as tumor vasculature and histology suggesting that observed changes may be rooted in altered tumor immune response following myofibroblast depletion (Figure 2). The gene discussed is CTLA4; the disease is neoplasm.